Navigation Links
Cylene to Present Advances with Industry's Only Clinical CK2 Inhibitor, CX-4945, at EORTC-NCI-AACR
Date:11/16/2010

SAN DIEGO, Nov. 16, 2010 /PRNewswire/ -- Cylene Pharmaceuticals, Inc. will present advances in the development of their first-in-class, CK2 inhibitor CX-4945, at the 22nd EORTC-NCI-AACR symposium on Molecular Targets and Cancer Therapeutics, to be held on November 16-19 in Berlin, Germany. CX-4945 is the first and only CK2 inhibitor to have entered clinical trials and represents an exciting new approach for the treatment for many different cancers. Three poster presentations will reveal results from the Phase I clinical trial and highlight the potential of this novel compound for combination anticancer therapies.

"We are delighted to be exhibiting so much fresh science around our flagship compound CX-4945. These scientific disclosures complement our manuscript describing the mechanism of action of CX-4945, recently accepted by the journal Cancer Research. Presentations by Cylene at premier conferences and the publication of our science by peer reviewed journals further validate CK2 as target for anticancer therapy," stated William Rice, PhD, President and CEO of Cylene Pharmaceuticals. "At the EORTC conference we will showcase the latest clinical data from patients treated with CX-4945 and also the discoveries concerning the critical roles that CK2 plays in the DNA Damage Response and EGF-Receptor pathways. These data provide a strong mechanistic rationale for the combination of CX-4945 with many agents that target these same pathways for the treatment of multiple cancers. As a company we aim to fully exploit the potential of CX-4945 in the clinic and ultimately see that it translates to real benefit for those patients and families struggling with cancer."

The presentation schedule is:

Wednesday, November 17, 2010: 12:00 PM Combined inhibition of EGFR and protein kinase CK2 synergistically blocks phosphorylation of ribosomal protein S6, induces apoptosis in cancer cells and displays enhanced antitumor activity in xenograft m
'/>"/>

SOURCE Cylene Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cylene to Present Advances in its Oral Inhibitor of CK2 at AACR Annual Meeting
2. Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2
3. Questcor to Present at the Maxim Group Growth Conference
4. Medco to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
5. Warner Chilcott to Present at the Bank of America Merrill Lynch Credit Conference
6. Regado Biosciences, Inc. Presents Two Abstracts on the Subcutaneous Depot Formulation of Pegnivacogin, a Nuclease-Stabilized RNA Aptamer, Direct Factor IXa Inhibitor and Part of the REG2 Anticoagulant System, at the American Heart Association (AHA)
7. WebMD to Present at the Citi 7th Annual U.S. Small/Mid Cap Conference
8. ERT to Present at Lazard Capital Markets 7th Annual Healthcare Conference on November 16, 2010
9. InfraReDx Announces Presentation of LipiScan™ Research at American Heart Association Scientific Sessions 2010
10. Philips and American Heart Association Present Fourth Annual Resuscitation Fellowship Award
11. HeartWare to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... "Copay coupons," a drug manufacturer ... drugs among patients with prescription drug coverage, may now be ... report  from the Department of Health and ... anti-kickback laws prohibit suppliers from offering side-payments to ... the federal government. The report ...
(Date:9/19/2014)... Today, iHealth Lab Inc. announced it has secured ... its first institutional round of funding. The strategic investment ... accelerate growth and innovation, and invest in additional sales ... Ventures will join iHealth,s board of directors, bringing added ... "We are very pleased to have Xiaomi ...
(Date:9/19/2014)... , Sept. 19, 2014 Kiromic, LLC, a ... of Kent Hance , the former chancellor of Texas ... retired as chancellor in July 2014, after raising $1.2 billion ... that Kent Hance , the most successful chancellor in ... team not only as an investor, but also as our ...
Breaking Medicine Technology:PCMA: New OIG Report Cites Drug Manufacturer "Copay Coupon" Use in Medicare Part D 2iHealth Raises $25 Million to Fuel Growth and Global Market Share 2Former Texas Tech Chancellor Named New Vice Chairman of the Board of Kiromic, LLC 2
... can be very serious for everybody. So serious, in fact, ... that nearly everyone get a flu vaccine. This is particularly ... people age, it becomes more difficult for them to fight ... of serious flu-related complications, including pneumonia, hospitalization and even death. ...
... Caremark Corporation (NYSE: CVS ) will be ... at 8:30 a.m. (ET) with analysts and investors to ... as its initial guidance for 2011. (Logo: ... call will be broadcast simultaneously through the Investor Relations ...
Cached Medicine Technology:Anthem Blue Cross and Blue Shield in Nevada Urges Seniors to Get Flu, Pneumonia Vaccines 2Anthem Blue Cross and Blue Shield in Nevada Urges Seniors to Get Flu, Pneumonia Vaccines 3Anthem Blue Cross and Blue Shield in Nevada Urges Seniors to Get Flu, Pneumonia Vaccines 4
(Date:9/22/2014)... In CHAMPS Patient Experience's most recent blog post, ... Meeting , Toya Gorley shares her thoughts on the ... Leader’s Board meeting this summer, which was comprised of ... to be exhilarating! Many topics were discussed, including:, ... the patient experience , Technology solutions ...
(Date:9/22/2014)... well-known wedding dress manufacturer and retailer, has recently announced a ... In addition, the company has also deiced to launch a ... in the new range is now provided with a deeply ... has thousands of unique special occasion outfits for sale; almost ... Its products are brand new and made with soft materials. ...
(Date:9/21/2014)... smoke, those using e-cigarettes (in addition to traditional cigarettes) ... to have quit smoking traditional cigarettes than non-users. Published ... of the American Cancer Society, the findings raise doubts ... patients give up smoking. , Because of the risks ... be advised to quit. But the rising use of ...
(Date:9/21/2014)... Phoenix, AZ (PRWEB) September 21, 2014 ... in Phoenix Arizona announces record demand for aggressively discounted ... of accidents occurring throughout the Valley each year, it ... to have access to discounted attorney’s fees as a ... said, Hastings and Hastings has been a frontrunner when ...
(Date:9/21/2014)... likely to trigger an allergy to peanuts than raw ... The researchers say that specific chemical changes caused by ... recognised by the body,s immune system, ,priming, the body ... time it sees any peanuts. , The results might ... peanut allergies in the Western world compared to populations ...
Breaking Medicine News(10 mins):Health News:CHAMPS' Toya Gorley Discusses the Thought-Provoking Conversation at The Leader’s Board Summer Meeting 2Health News:Discounted Plus Size Wedding Dresses Available At Fancyflyingfox.com 2Health News:E-cigarettes unhelpful in smoking cessation among cancer patients 2Health News:Hastings & Hastings Announces Record Demand For Aggressively Discounted Accident Victim Attorney’s Fees 2Health News:Hastings & Hastings Announces Record Demand For Aggressively Discounted Accident Victim Attorney’s Fees 3Health News:Dry roasting could help trigger peanut allergy 2
... Rochester study helps to explain why men get liver cancer more ... pathway, by showing a direct link between the androgen receptor, which ... it relates to the deadly cancer. The study is published ... journal from the American Association for the Advancement of Science, AAAS. ...
... ... , ... today unveiled a men,s line of wallets2wear, the revolutionary new line of wearable wallets. These ... carry a man,s credit card, ID, cash and key. They are convenient, clever and comfortable., , ...
... ... out why. This sweepstakes takes the winner and three guests to the beautiful Bay Of ... trip for four for bloggers who enter the kiwi a-go-go contest. No purchase necessary. ... (PRWEB) May 20, 2010 -- ...
... have received a $3.3 million National Institutes of Health ... and language development in bilingual children who speak English ... with those who have no delays. "Spanish speakers ... and make up 79 percent of the school age ...
... ... addresses the rise of ADHD based on scientific evidence, including toxins such as pesticides, ... public , ... May 19, 2010 -- A new book on ADHD by Dr. Sanford Newmark, one ...
... likely to develop problem , WEDNESDAY, May 19 (HealthDay ... other similar medications, may prompt long-term hearing loss among ... 18 issue of the Archives of Otolaryngology -- ... of Alabama at Birmingham discuss evidence supporting an association ...
Cached Medicine News:Health News:Androgen receptor may explain male dominance in liver cancer 2Health News:Androgen receptor may explain male dominance in liver cancer 3Health News:Androgen receptor may explain male dominance in liver cancer 4Health News:Wallets2wear Now Available for Men 2Health News:Win A Trip To New Zealand For Four: The Great Kiwi Adventure and ZESPRI's Kiwi A-Go-Go Bloggers' Contest 2Health News:Researchers get $3.3 million grant to investigate language outcomes of bilingual children 2Health News:Book Delivers Latest ADHD Research, Treatments & Results 2Health News:Book Delivers Latest ADHD Research, Treatments & Results 3Health News:Viagra Linked to Hearing Loss 2
Anti-Skin Antibody (ASA) Test Kit: Pemphigus and Bullous Pemphigoid...
... Medical Professional Diagnostics is a leading provider ... and DFA test menu that includes kits ... as well as miscellaneous conjugates and components. ... a wide assortment of substrates and kit ...
... technologies and designs, the Digital ClearMag ... of the posterior pole. Using this ... previously unattainable with the binocular indirect ... and comprehensive views, helping to reduce ...
... Our ELISA products for autoimmune testing ... ELISAs, as well as specific reflex tests ... Sm, Sm/RNP, SS-A (Ro), SS-B (La), Scl-70 ... family includes a full line of products ...
Medicine Products: